Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Fragile underlying quality score of 28/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street sentiment is generally neutral alongside robust expected earnings growth. However, capital return yields remain modest, anchored by a strong, well-covered dividend yield.
BWSN struggles with subpar profitability and pressured margins. However, this is severely offset by a highly leveraged balance sheet (Debt/EBITDA > 4.0x) and elevated financial risk.
The company is facing top-line contraction (-1.2% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 5.2%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $161.0M | -18.1% | -1.2% | +0.7% | -10.4% | |
| EBITDA | $15.1M | — | +13.1% | — | — | |
| Net Income | $9.3M | +39.7% | -16.4% | — | — | |
| EPS (Diluted) | $0.05 | +41.5% | — | — | — | |
| Free Cash Flow | -$7.2M | +34.0% | -25.0% | -11.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 25.5% | 24.5% | 24.4% | 17.5% |
| Operating Margin | 5.2% | 3.2% | 2.4% | -5.6% |
| Net Margin | -5.7% | -13.9% | -8.2% | -15.7% |
| FCF Margin | -13.5% | -13.3% | -12.7% | -13.5% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q1'26Latest | — | $-0.32 | — | ||
| Q1'26 | — | $-0.32 | — | ||
| Q4'25 | $-0.09 | $0.34 | +493.2% | ||
| Q3'25 | $-0.09 | $-0.22 | -143.5% | ||
| Q2'25 | $-0.13 | $-0.26 | -97.0% | ||
| Q1'25 | $-0.01 | $-0.83 | -6112.3% | ||
| Q3'23 | — | $-2.25 | — | ||
| Q2'23 | — | $-0.10 | — |
Total return is +33.0% (1Y), outperforming the benchmark by +8.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | — | — | — |
| 1Y | +33.0% | +8.0% | +5.2% |
| 3YCAGR | +8.1% | -11.4% | +21.2% |
| 5YCAGR | +5.5% | -6.9% | +34.9% |
| 10YCAGR | +3.2% | -10.4% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Babcock & Wilcox Enterprises, I (BWSN) valuation, health, and returns.
Babcock & Wilcox Enterprises, I is estimated to be fairly valued under our discounted cash flow framework. relative multiples indicate the stock is Limited: Expensive versus peers compared to industry peers. trading near fair value (DCF: $0.00)
Babcock & Wilcox Enterprises, I has multiple valuation anchors: DCF Intrinsic Value: $0.00 | Peer Relative Fair Value: $2.09. A convergence of these signals offers higher conviction.
Babcock & Wilcox Enterprises, I displays weak financial health with a composite quality score of 28/100, supported by a Altman Z-Score of -1.3 (distress zone), Piotroski F-Score of 2/9, Return on Invested Capital (ROIC) of 9.1%.
Babcock & Wilcox Enterprises, I pays a 0.8% dividend yield, covered by a 0% payout ratio with 0 years of growth, supplemented by a 0.0% buyback yield.
Babcock & Wilcox Enterprises, I's current growth trajectory is Decelerating. The company achieved -18.1% 1Y revenue growth and +41.5% 1Y EPS growth, compared to its 3Y revenue CAGR of -1.2%.
Wall Street consensus is Hold based on 0 analysts, beating EPS expectations in 25% of recent quarters with a 1-quarter streak. The consensus price target represents a N/A change from current levels.
Investment risks for Babcock & Wilcox Enterprises, I include: -5.1% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.15x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.